MUMBAI, India, Nov. 2 -- Intellectual Property India has published a patent application (202648126264 A) filed by Institut Pasteur De Lille; and Institut National De La Sant Et De La Recherche on October 23, 2026, for Bordetella Strains Stably Expressing Serotype-3 Fimbriae And Methods Of Making The Same.
Inventors include Debrie, Anne-Sophie; Raze, Dominique; and Locht, Camille.
The application for the patent was published on October 30, 2026, under issue no. 44/2026.
Abstract: ABSTRACT BORDETELLA STRAINS STABLY EXPRESSING SEROTYPE-3 FIMBRIAE AND METHODS OF MAKING THE SAME The present disclosure relates to Bordetella strains engineered to stably express serotype-3 fimbriae (Fim3), including strains that stably produce both serotype-2 fimbriae (Fim2) and Fim3. The disclosure further relates to live attenuated Bordetella strains deficient in at least one functional virulence factor selected from pertussis toxin (PTX), dermonecrotic toxin (DNT), and tracheal cytotoxin (TCT). The disclosure further relates to methods of producing the engineered strains and methods of preparing vaccines comprising the engineered strains and a pharmaceutically acceptable carrier.
Disclaimer: Curated by HT Syndication.
